Argos Wealth Advisors LLC Makes New $673,000 Investment in Edwards Lifesciences Corporation $EW

Argos Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 7,900 shares of the medical research company’s stock, valued at approximately $673,000.

Other large investors have also bought and sold shares of the company. JPL Wealth Management LLC purchased a new position in shares of Edwards Lifesciences in the third quarter valued at $25,000. Kohmann Bosshard Financial Services LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $28,000. Hantz Financial Services Inc. grew its position in shares of Edwards Lifesciences by 76.6% in the third quarter. Hantz Financial Services Inc. now owns 378 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 164 shares in the last quarter. Dorato Capital Management purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $29,000. Finally, Rakuten Securities Inc. grew its position in shares of Edwards Lifesciences by 413.7% in the second quarter. Rakuten Securities Inc. now owns 375 shares of the medical research company’s stock valued at $29,000 after purchasing an additional 302 shares in the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Edwards Lifesciences Price Performance

NYSE:EW opened at $79.69 on Wednesday. The firm has a market capitalization of $45.88 billion, a price-to-earnings ratio of 42.39, a P/E/G ratio of 1.94 and a beta of 0.87. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $87.89. The stock has a fifty day moving average of $81.78 and a 200 day moving average of $82.80. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.63 and a current ratio of 4.42.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. The company had revenue of $1.65 billion during the quarter, compared to analyst estimates of $1.60 billion. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the company earned $0.64 earnings per share. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. On average, research analysts expect that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Insiders Place Their Bets

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 22,680 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $80.16, for a total transaction of $1,818,028.80. Following the completion of the sale, the vice president owned 21,266 shares of the company’s stock, valued at $1,704,682.56. The trade was a 51.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Scott B. Ullem sold 13,000 shares of Edwards Lifesciences stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total value of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares of the company’s stock, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 88,096 shares of company stock valued at $7,288,799 over the last 90 days. Insiders own 0.31% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on EW shares. UBS Group reiterated a “neutral” rating and issued a $94.00 price target on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Evercore reiterated an “outperform” rating and issued a $93.00 price target on shares of Edwards Lifesciences in a research report on Friday, April 24th. The Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 price target (down from $108.00) on shares of Edwards Lifesciences in a research report on Wednesday, February 11th. Barclays reiterated an “overweight” rating and issued a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research report on Monday, April 27th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of Edwards Lifesciences in a research report on Monday, April 20th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, Edwards Lifesciences has a consensus rating of “Moderate Buy” and an average target price of $95.65.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.